R. Maclean

Treatment impact on estimated medical expenditure and job loss likelihood in rheumatoid arthritis: re-examining quality of life outcomes from a randomized placebo-controlled clinical trial with abatacept (2008)

Cole, J. C., Li, T., Lin, P., MacLean, R., Wallenstein, G. V.

Objectives. Quality of life (QoL) improvement is important to demonstrate in RA clinical trials, but can be abstract. More meaningful measures of QoL include medical expenditure and job loss, aspects...

An index of only patient-reported outcome measures, routine assessment of patient index data 3 (RAPID3), in two abatacept clinical trials: similar results to disease activity score (DAS28) and other RAPID indices that include physician-reported measures (2008)

Pincus, T., Bergman, M. J., Yazici, Y., Hines, P., Raghupathi, K., Maclean, R.

Objectives. To analyse the capacity of routine assessment of patient index data 3 (RAPID3), an index of only the three patient-reported outcome (PRO) measures in the RA Core Data Set—physical...

Cost-effectiveness of abatacept in patients with moderately to severely active rheumatoid arthritis and inadequate response to methotrexate (2008)

Vera-Llonch, M., Massarotti, E., Wolfe, F., Shadick, N., Westhovens, R., Sofrygin, O., ...

Objective. To assess cost–effectiveness of abatacept in patients with moderately to severely active RA and inadequate response to MTX. Methods. We developed a simulation model to depict progression...

Improved health-related quality of life for rheumatoid arthritis patients treated with abatacept who have inadequate response to anti-TNF therapy in a double-blind, placebo-controlled, multicentre randomized clinical trial (2006)

Cole, J C, Li, T, Maclean, R, Lin, P, ...

OBJECTIVE: Rheumatoid arthritis (RA) patients who have inadequate response to anti-tumour necrosis factor (TNF) therapy currently have treatment options that are limited and less than optimal in...

Improved health-related quality of life for rheumatoid arthritis patients treated with abatacept who have inadequate response to anti-TNF therapy in a double-blind, placebo-controlled, multicentre randomized clinical trial (2006)

Westhovens, R., Cole, J. C., Li, T., Martin, M., MacLean, R., Lin, P., ...

Objective. Rheumatoid arthritis (RA) patients who have inadequate response to anti-tumour necrosis factor (TNF) therapy currently have treatment options that are limited and less than optimal in...

Improved health-related quality of life for rheumatoid arthritis patients treated with abatacept who have inadequate response to anti-TNF therapy in a double-blind, placebo-controlled, multicentre randomized clinical trial (2006)

Westhovens, R., Cole, J. C., Li, T., Martin, M., MacLean, R., Lin, P., ...

Objective. Rheumatoid arthritis (RA) patients who have inadequate response to anti-tumour necrosis factor (TNF) therapy currently have treatment options that are limited and less than optimal in...

Improved health-related quality of life for rheumatoid arthritis patients treated with abatacept who have inadequate response to anti-TNF therapy in a double-blind, placebo-controlled, multicentre randomized clinical trial (2006)

Westhovens, R., Cole, J. C., Li, T., Martin, M., MacLean, R., Lin, P., ...

Objective. Rheumatoid arthritis (RA) patients who have inadequate response to anti-tumour necrosis factor (TNF) therapy currently have treatment options that are limited and less than optimal in...

Teacher Education for sustainability in the Asia-Pacific region (2000)

Fien, John Francis, Maclean, R.